Publication Name	World Journal of Hepatology
Manuscript ID	26921
Country	China

Received	2016-04-29 15:31
Peer-Review Started	2016-05-04 13:54
To Make the First Decision	2016-07-04 16:49
Return for Revision	2016-07-05 10:37
Revised	2016-07-06 10:48
Second Decision	2016-07-21 17:20
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-08-01 15:30
Articles in Press	2016-08-01 15:30
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-08-09 10:02
Publish the Manuscript Online	2016-08-17 08:44

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial
Manuscript Source	Unsolicited Manuscript
All Author List	Jian-Hong Zhong, Xue-Ke Du, Bang-De Xiang and Le-Qun Li
Funding Agency and Grant Number	Funding Agency Grant Number Guangxi Science and Technology Development Projects 14124003-4 Guangxi University of Science and Techno­logy Research Projects KY2015LX056 the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province Z2015621 the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province Z2015601 the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province GZZC15-34 the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province Z2014241 the Innovation Project of Guangxi Graduate Education YCBZ2015030
Corresponding Author	Le-Qun Li, MD, Department of Hepato­biliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, He Di Rd #71, Nanning 530021, Guangxi Zhuang Autonomous Region, China. xitongpingjia@163.com
Key Words	Adjuvant; Hepatocellular carcinoma; Tumor recurrence; Sorafenib
Core Tip	Sorafenib is effective for advanced hepato-cellular carcinoma (HCC). However, its positive role as adjuvant therapy for HCC after surgery or transarterial chemoembolization is controversy.
Publish Date	2016-08-17 08:44
Citation	Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: a cautionary comment of STORM trial. World J Hepatol 2016; 8(23): 957-960
URL	http://www.wjgnet.com/1948-5182/full/v8/i23/957.htm
DOI	http://dx.doi.org/10.4254/wjh.v8.i23.957

Full Article (PDF)	WJH-8-957.pdf
Full Article (Word)	WJH-8-957.doc
Manuscript File	26921-Review.docx
Answering Reviewers	26921-Answering reviewers.pdf
Audio Core Tip	26921-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	26921-Conflict-of-interest statement.pdf
Copyright License Agreement	26921-Copyright assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	26921-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate	26921-Language certificate.pdf
Peer-review Report	26921-Peer-review(s).pdf
Scientific Misconduct Check	26921-Scientific misconduct check.pdf
Scientific Editor Work List	26921-Scientific editor work list.pdf